Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Investors often face a choice between the stability of established giants and the high-stakes potential of clinical-stage innovators. Deciding between Amgen (NASDAQ:AMGN) and CRISPR Therapeutics (NASDAQ:CRSP) requires balancing immediate dividends against long-term scientific breakthroughs. Amgen is a global leader in traditional drug manufacturing with a vast portfolio of approved therapies. In contrast, CRISPR Therapeutics is a pioneer in gene-editing technology, recently launching its first commercial product. This comparison explores which approach offers a more compelling opportunity for your portfolio in 2026. Amgen develops medicines for heart disease, obesity, and rare diseases among healthcare stocks . Its portfolio includes treatments for inflammatory conditions and various cancers, serving patients in more than 100 countries. The company distributes products primarily through three wholesalers: McKesson (NYSE:MCK) , Cencora (NYSE:COR) , and Cardinal Health (NYSE:CAH) . These three companies accounted for nearly 77% of worldwide gross revenues in 2025. Customer concentration like this adds a layer of risk to the business. Continue reading